Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (964)	1/11/1999 6:04:00 PM
From: jerryriti	Respond to of 1477

Scios has 2 major programs. A NDA has been filed with the FDA for Natrecor and approval should be forthcoming within weeks! This is the first new treatment for acute congestive heart failure in decades. There are various projections for the revenue stream, but I would have to do some digging into my notes. Suffice it to say, with approval, the market will develop rapidly(do not beleive they have signed on the dotted line for partnering on this product but could be wrong) Second program involves Fiblast for stroke. Truthfully, I am not up on the status of this program as I came into this stock vis a vis the Natrecor story! Scios has numerous collaborations with many drug houses and they market for others psychiatric medications (Paxil) which contributes modestly to its earnings. Sorry to be so sketchy, but wanted to give you a guideline!

To: BRAVEHEART who wrote (964)	1/11/1999 6:36:00 PM
From: ubrx	Read Replies (1) \| Respond to of 1477

LoneWolf, Take a look at the company website sciosinc.com Click on investor relations and read all the press releases from the last two years. Natrecor is the product that comes before the FDA Cardiology Committee later this month. A positive recommendation will likely lead to approval within a short time. Bayer is the marketing partner on Natrecor. Scios will receive a 20 million dollar milestone payment upon FDA approval. Scios should gross about 30% in royalties on Natrecor sales. The size of the market is the subject of much debate. I have heard projections of 100-500 million per year depending on who is predicting. Short term everything depends on the Cardiology committee. Anything less than a recommendation for approval will crash the stock. Good Luck, Jim BTW, the Yahoo thread for SCIO is more active than this one and worth looking at.